PAION : ANNOUNCES ATTENDANCE AT FOUR UPCOMING CONFERENCES

DGAP-News: PAION AG / Key word(s): Conference PAION ANNOUNCES ATTENDANCE AT FOUR UPCOMING CONFERENCES 12.09.2018 / 14:00 The issuer is solely responsible for the content of this announcement. PAION ANNOUNCES ATTENDANCE AT FOUR UPCOMING CONFERENCES Aachen (Germany), 12 September 2018 - The specialty pharma company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange Prime Standard: PA8) today announces its participation in four upcoming conferences. PAION AG representatives will be available for one-on-one meetings at these events. Baader Investment Conference 24 - 27 September 2018 Sofitel Munich Bayerpost Munich, Germany http://www.baaderinvestmentconference.com BIO-Europe 05 - 07 November 2018 Bella Center Copenhagen, Copenhagen, Denmark https://ebdgroup.knect365.com/bioeurope/ Jefferies 2018 London Healthcare Conference 14 - 15 November 2018 Waldorf Hilton London, United Kingdom https://www.jefferies.com/OurFirm/Conferences/325/413 Deutsches Eigenkapitalforum 26 - 28 November 2018 Sheraton Frankfurt Airport Hotel & Conference Center Frankfurt a.M., Germany https://www.eigenkapitalforum.com ### About PAION PAION AG is a publicly listed specialty pharmaceutical company developing and aiming to commercialize innovative drugs for out-patient and hospital-based sedation, anesthesia and critical care services. PAION's lead compound is remimazolam, an intravenous, ultra-short-acting and controllable benzodiazepine sedative/anesthetic drug candidate for which PAION has completed the clinical development for use in procedural sedation in the U.S. Outside the U.S., PAION is currently focused on the development of remimazolam for general anesthesia. A full clinical development program for general anesthesia has been completed in Japan. In the EU, PAION initiated a Phase III trial in July 2018. Development of remimazolam for intensive care unit (ICU) sedation is also part of the longer-term life-cycle plan for remimazolam. PAION's vision is to become an acknowledged "PAIONeer" in sedation and anesthesia. PAION is headquartered in Aachen (Germany) with an additional site in Cambridge (United Kingdom). PAION Contact Ralf Penner Vice President Investor Relations/Public Relations PAION AG Martinstrasse 10-12 52062 Aachen - Germany Phone: [phone] E-mail: [e-mail] www.paion.com Disclaimer: This release contains certain forward-looking statements concerning the future business of PAION AG. These forward-looking statements contained herein are based on the current expectations, estimates and projections of PAION AG's management as of the date of this release. They are subject to a number of assumptions and involve known and unknown risks, uncertainties and other factors. Should actual conditions differ from the Company's assumptions, actual results and actions may differ materially from any future results and developments expressed or implied by such forward-looking statements. Considering the risks, uncertainties and other factors involved, recipients should not rely unreasonably upon these forward-looking statements. PAION AG has no obligation to periodically update any such forward-looking statements to reflect future events or developments. 12.09.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

Language:	English
Company:	PAION AG
	Martinstr. 10-12
	52062 Aachen
	Germany
Phone:	[phone]
Fax:	[phone]
E-mail:	[e-mail]
Internet:	www.paion.com
ISIN:	DE000A0B65S3
WKN:	A0B65S
Listed:	Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange

End of News	DGAP News Service

722819  12.09.2018